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ABSTRACT: The use of mass spectrometry coupled with chemical cross-linking of proteins has become a powerful tool for
proteins structure and interactions studies. Unlike structural analysis of proteins using chemical reagents specific for lysine or
cysteine residues, identification of gas-phase fragmentation patterns of endogenous dityrosine cross-linked peptides have not
been investigated. Dityrosine cross-linking in proteins and peptides are clinical markers of oxidative stress, aging, and
neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. In this study, we investigated and characterized
the fragmentation pattern of a synthetically prepared dityrosine cross-linked dimer of Aβ(1−16) using ESI tandem mass
spectrometry. We then detailed the fragmentation pattern of dityrosine cross-linked Aβ(1−16), using collision induced
dissociation (CID), higher-energy collision induced dissociation (HCD), electron transfer dissociation (ETD), and electron
capture dissociation (ECD). Application of these generic fragmentation rules of dityrosine cross-linked peptides allowed for the
identification of dityrosine cross-links in peptides of Aβ and α-synuclein generated in vitro by enzymatic peroxidation. We report,
for the first time, the dityrosine cross-linked residues in human hemoglobin and α-synuclein under oxidative conditions. Together
these tools open up the potential for automated analysis of this naturally occurring post-translation modification in
neurodegenerative diseases as well as other pathological conditions.
Posttranslational modifications (PTMs) of newly synthesizedproteins modulate their function, localization, enzymatic
activity, and structural stability.1 The array of modifications
provides the potential to increase the number of protein products
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of a given genome.2 Many PTMs are also dependent upon the
interaction of the organism with external environmental factors.
Oxidative and nitrative stress is a ubiquitous feature of aerobic
metabolism and can directly modify proteins to alter structure
and function.3 Oxidative stress and endogenous mechanisms can
result in the covalent cross-link between two tyrosine residues
resulting in the formation of a dityrosine (DT) post translational
modification.4 Since Gross and Sizer synthesized dityrosine by
enzymatic peroxidation and Anderson demonstrated that
dityrosine is present in the hydrolysates of resilin, many
structural protein hydrolysates have been shown to contain
dityrosine.5,6 Proteins with dityrosine cross-links have been
identified in many vertebrate and invertebrate connective tissues
as a product of normal PTMs contributing to their stability,
elasticity, and integrity.6−9 Dityrosine cross-linking in proteins
can be promoted by oxidizing agents such as hydroxyl radical,
peroxynitrite, nitrosoperoxycarbonate, and lipid hydroperoxides
as well as ultraviolet and γ-irradiation.10 Enzymatic oxidation of
tyrosine (Tyr) residues in proteins by peroxidase-catalyzed
mechanism has been found to promote dityrosine cross-links. In
vitro, dityrosine cross-linking of proteins such as lysozyme,
calmodulin, myoglobin, hemoglobin, insulin, and RNase is
known to occur as a product of oxidative/nitrative stress.11
Dityrosine has also been identified as a clinical biomarker of
oxidative stress, aging, and diverse pathological conditions.
Dityrosine has been found in Alzheimer’s Disease (AD),12
Parkinson Disease (PD),13 lipofuscin granules in the human
brain,14 and cerebrospinal fluid.15 Enrichment of dityrosine
cross-linked low density lipoproteins (LDL) have been reported
in human atherosclerotic lesions and plaques.16 Elevated levels of
protein-bound dityrosine have been reported in the blood
plasma of patients with chronic renal failure,17 while diabetic
patients have higher levels of free dityrosine in their urine.18 The
advantage of evaluating dityrosine as a biomarker for oxidative/
nitrative stress is based upon (i) its chemical stability (unreactive
to the changes in oxygen/pH), (ii) free dityrosine is not
incorporated in de novo proteins synthesis, and (iii) dityrosine is
released after proteolysis of oxidatively modified proteins.4
Hence, quantitative determination of the levels of dityrosine
reflects the extent of oxidative and/or nitrative stress on
endogenous proteins.2 Current quantitation of dityrosine from
protein hydolysates is achieved by the measurement of a
characteristic fluorescence at 420 nm upon excitation at either
315 nm (alkaline solutions) or 284 nm (acidic solutions).19 Use
of mass spectrometric quantitation of free dityrosine in biological
samples has emerged as a critical analytical tool.2 Quantitative
detection of free dityrosine has been performed using isotopic
dilution gas chromatography coupled to mass spectrometry
(GC-MS/MS) as well as liquid chromatography coupled to ESI-
MS/MS in urine and eye lens protein hydrolysates.20,21
Despite these advancements in quantitatively determining free
dityrosine, there is a lack in our ability to determine the specific
protein targets involved in the dityrosine cross-link. Routine
application of LC−MS/MS-based proteomics for many PTMs
such as phosphorylation and ubiquitination is quite common, but
dityrosine cross-linked peptides sequences are yet to be widely
analyzed.22 Identification of dityrosine cross-linked peptides like
any other cross-linked peptides poses a challenge as data
complexity increases as a square of the number of proteins and
potential cross-linking sites (the n2 problem).23 To overcome
these limitations, we investigated various commonly used gas-
phase fragmentation techniques to determine if there was a
characteristic fragmentation for the synthetically prepared
dityrosine cross-linked Aβ dimer in ESI-MS/MS that could be
used to develop a characteristic set of fragmentation rules. In this
report, we discuss the fragmentation pattern of dityrosine cross-
linked Aβ(1−16) dimer using collision-induced dissociation
(CID), higher-energy collision induced dissociation (HCD),
electron transfer dissociation (ETD), and electron capture
dissociation (ECD). This allowed us to propose a generic
workflow for the identification of dityrosine cross-linked
peptides, which led to successful identification of novel
dityrosine cross-links in human hemoglobin and α-synuclein.
This work flow provides the foundation for the identification of
protein pairs involved in endogenous dityrosine cross-links.
■ MATERIALS AND METHODS
Sample Preparation. Protein concentrations were deter-
mined using UV−visible spectroscopy (for hemoglobin ε405 nm =
178000 M−1 cm−1, α-synuclein ε280 nm = 5120 M
−1 cm−1, and
Aβ(1−42) ε214 nm = 94526M−1 cm−1). Hemoglobin from Sigma-
Aldrich (H7379) was prepared by dissolving in phosphate buffer
saline (PBS, 137 mMNaCl, 2.7 mMKCl, 10 mMNa2HPO4, and
1.8 mM KH2PO4) pH 7.4. See the Supporting Information for
Aβ(1−42) and α-synuclein stock solution preparation. Hydro-
gen peroxide (H2O2) solutions were freshly prepared by diluting
a 30% stock (Merck) solution to an appropriate concentration;
the concentration of the diluted stock was estimated using the
ε240 nm = 43.6 M
−1 cm−1.
In vitro Dityrosine Cross-Link Generation in Proteins.
In this study, the peroxidase activity of hemoglobin was used to
generate dityrosine cross-links in Aβ(1−42) and α-synuclein.
Five micromolar hemoglobin was incubated with H2O2 (100
μM) for 10 min to produce the active catalyst (ferrylhemoglo-
bin). To this solution, recombinant α-synuclein or Aβ(1−42)
was added to a final concentration of 20 and 25 μM, respectively.
Following this, each sample was then incubated with 20 μM
H2O2 (final concentration) at room temperature for 30 min. The
control samples were prepared without any Hb. The cross-linked
oligomeric Aβ(1−42) or α-synuclein samples were centrifuged
for 5 min and then the supernatant (100 μL) was loaded on to a
Superdex 75 10/300 GL size exclusion column (GE Healthcare
Life Science) at a flow rate of 0.75 mL/min. Fractions of 0.8 mL
were collected using an AKTA fraction collector (Amersham
Biosciences).
Data Analysis and Identification of Dityrosine Cross-
Linked Peptides. Analyses of the fragment ion of the ESI-MS/
MS data for the synthetic dityrosine cross-linked Aβ(1−16)
dimer was performed manually in Agilent Qualitative Mass
Hunter software (CID on the Q-TOF) and Xcalibur software
(HCD and ETD on the LTQOrbitrap Elite). The nomenclature
for naming the product ions generated from either by single
backbone cleavage or multiple cleavages during charge-remote
fragmentation processes was used for annotating the MS/MS
spectra. Besides manual analysis of dityrosine cross-linked
peptides, a combination of software tools such as StavroX,24
which was designed specifically for cross-linked analysis, and
standard database search tools such as Mascot were used in order
to gain further insight into the specific fragmentation processes of
dityrosine cross-linked peptides.25 Dityrosine cross-linked
peptides were considered significant if both the standard Mascot
search and Stavrox analysis were concordant. The available
crystal structures from PDB (2DN2 for hemoglobin and 1XQ8
for α-synuclein) were used to visualize proteins. Modeling and
analysis of proteins to generate the final models of dityrosine
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cross-link sites in proteins was performed in UCSF CHI-
MERA.26 Cross-link map was generated using xiNET.27
■ RESULTS
Gas-Phase Fragmentation of Synthetic Dityrosine
Cross-Linked Aβ. Peptide sequencing by tandem mass
spectrometry forms the basis of bottom-up (shotgun)
proteomics. The most common and informative ions are
generated by fragmentation at the amide bond between amino
acids in tandem mass spectrometry. For the dityrosine cross-
linked peptides, we adapted a nomenclature for the possible
fragments (Figure S1) that contain both the cross-link and the
interpeptide, designating the longer chain as α and the smaller
chain β (Figure S1, Schilling nomenclature).28 We used a
Figure 1.Characterization of gas-phase fragmentation dityrosine cross-linked peptide. (a) The annotated CID ESI-MS/MS spectra of the homodimeric
dityrosine cross-linked Aβ(1−16). The precursor ion [M+5H]5+ at m/z 782.1417 was selected for fragmentation for CID with collision energy of 23.4
eV on a 6550 Q-TOF. (b) Annotated HCDESI-MS/MS spectrum of homodimeric dityrosine cross-linked Aβ(1−16) on LTQ-Orbitrap. The precursor
ion [M+5H]5+ at m/z 782.1417 was targeted for fragmentation with a normalized collision energy of 35 eV and the activation time of 0.1 ms. (c)
Annotated ETDMS/MS spectrum of homodimeric dityrosine cross-linked Aβ(1−16) with the precursor ion [M+5H]5+ atm/z 782.15 was targeted for
fragmentation with the ETD reagent for 1 ms. (d) Annotated ECD MS/MS spectrum of homodimeric dityrosine cross-linked Aβ(1−16) with the
precursor ion [M+5H]5+ at m/z 782.15 using electrons produced from EMS cell. (e) Schematic representation of gas-phase fragmentation mechanism
and feasible product ions from dityrosine cross-linked peptide. Amino acid residues of the peptide side chains of the dityrosine cross-linked peptide has
been labeled as A and tyrosine has been labeled Y.
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simplified nomenclature to label homodimeric dityrosine cross-
links, where fragments containing the cross-link were designated
with an α (e.g., b12α). To investigate the fragmentation pattern
and formulate generic rules for dityrosine cross-linked peptides,
synthetically prepared dityrosine cross-linked Aβ(1−42) with
oxidized Met35 (sulfoxy methionine) was taken as a model
system. High-resolution HPLC-ESI-MS of the synthetic
dityrosine cross-linked Aβ(1−42) peptide displayed a charge
envelope with expected [M + 6H]6+, [M + 7H]7+, and [M +
8H]8+ ions with m/z 1510.5747, 1295.0597, and 1133.1810
(Figure S2a), respectively. However, this model peptide was not
used subsequently due to (i) its high hydrophobicity-induced
aggregation on C18 column and (ii) poor elution profile.
We next investigated the proteolytic digestion of the dityrosine
cross-linked Aβ(1−42) under denaturing conditions with LysC
before MS/MS analysis. The ESI-Q-TOF of the digested
dityrosine cross-linked Aβ(1−42) dimer resulted in a dityrosine
cross-linked Aβ(1−16) dimer with a charge envelope from z =
8−3 (Figure S2b). The CID fragmentation pattern of this
peptide at precursor [M + 5H]5+ ion withm/z 752.1471 is shown
in Figure 1a. The C-terminal of the dityrosine cross-linked
peptide in theMS/MS spectrum was covered by the series of y1−
y6 ions, while the N-terminal sequence was mostly covered by the
series of b2−b8 product ions (Figure 1a). Additionally, product
ions with the dityrosine cross-link intact were also observed in
the CID spectrum as indicated by the highly charged series y8α−
y15α ions, along with b13α (Figure 1a).We did not see any cleavage
of the C−C bond between aromatic rings of dityrosine yielding
monomeric Aβ(1−16). High pH reversed phase HPLC of the
proteolytically digested dityrosine cross-linked Aβ(1−42) using
a fluorescence detector indicated the presence of an equimolar
mixture of two dityrosine cross-linked peptides (Figure S3a).29,30
While peak 1 corresponds to dityrosine cross-linked Aβ(1−16)
dimer as verified from ESI-MS/MS (Figure 1a), the structure of
the other LysC-digested dityrosine cross-linked Aβ dimer
corresponding to peak 2 was confirmed by ESI-MS/MS to be
a heterodimer of Aβ(1−16 and 1−10) resulting from incomplete
peptide synthesis (Figure S3b).30 The CID fragmentation
pattern for the heterodimeric dityrosine cross-linked peptide
(Figure S3b) was found to be similar to that of the homodimeric
dityrosine cross-linked Aβ(1−16) peptide. Higher-energy C-trap
dissociation (HCD) on a LTQOrbitrap Elite resulted in a similar
fragmentation pattern observed with CID for homodimeric
dityrosine cross-linked Aβ(1−16) peptide (Figure 1b).
Electron transfer dissociation (ETD) and electron capture
dissociation (ECD) by electron transfer/capture to protonated
peptides causing random peptide backbone breakage are a
nonergodic process (not involving intramolecular vibrational
energy redistribution) unlike CID/HCD.31 ETD/ECD is also
preferred for protonated peptides with high charge states and
have been used successfully for sequencing large proteins.32
Different types of fragmentation products were observed in the
ETD spectra of homodimeric dityrosine cross-linked Aβ(1−16)
peptide in Orbitrap Fusion Lumos (Figure 1c and Figure S4) by
targeting the [M + 5H]5+ ion (m/z 782.1417) with increasing
reaction time. ETD spectrum even with the lowest ETD reaction
time of 1 ms (Figure 1c) showed complete amino acid sequence
except for the lowest c1
+ and z1
+ fragments that were beyond the
mass range used where observation of their counterpart ions
z15α
3+ and c15α
3+ assisted in the assignment of the respective N-
and C-termini amino acids. Registration of the cnα and znα
fragment ions indicates the fragmentation of one side chain
across the dityrosine cross-link with the other peptide chain
intact. The intensity of the c2
+ and c3+ ions was very weak under
these experimental conditions, but application of the ETD
supplemental activation (combination of ETD and HCD at 10%
normalized collision energy) resulted in a marked intensity
increase consistent with an activation barrier in the formation of
these fragment ions. At the ETD reaction time of 1 ms, 5+ charge





5+ ions was unexpected and may be
due to simultaneous electron autodetachment similar to
vibrational excitation of small molecules by electrons through
the formation of short-lived negative ion resonances.33 The 4+
charge reduced species fragmented via formation of two pairs of
complementary ions: (i) 4+ charge fragments and neutral
counterparts and (ii) 3+ and 1+ charge states fragments. Both
pathways were observed in the ETD spectrum with 1ms reaction
time (Figure 1c). A third type of fragmentation from the 4+
reduced ions into two counterpart ions both with 2+ charge
states were not observed. 3+ reduced ions did not fragment into
doubly charged fragments either. Increasing the ETD reaction
time to 5 and 10 ms resulted in further reduction of the precursor
ions to 2+ charge reduced states along with the observation of
doubly charged fragment ions; since their real precursor ions are
2+ reduced ions, the counterpart species for these doubly
charged fragment ions are neutral fragments. Singly charged
reduced ions and fragment ions with another peptide chain intact
started to appear for the ETD reaction time 15 ms and longer
(Figure S4). Although these spectra were obtained with [M +
5H]5+ precursor ions, nevertheless, higher ETD reaction time
spectra show ETD type fragmentation of reduced species rather
than that of the selected precursor. Therefore, only ETD
spectrumwith 1ms reaction time (Figure 1c) can bemost closely
related to the ETD spectrum of the [M + 5H]5+ precursor ions.
Similar fragmentation pattern along with reduced species of the
precursor [M + 5H]5+ ion were observed both in the ECD
reaction using electrons produced by EMS cell (Figure 1d) as
well as in FT-ICR-MS/MS (Figure S5), although ECD was not
as detailed as ETD fragmentation.
The fragmentation features for dityrosine cross-linked
homodimeric and heterodimeric peptides followed specific
general rules (Figure 1e). First, the fragmentation of the peptide
chains led to the cleavage on either side of the dityrosine cross-
linking site similar to that observed in linear peptides. Second,
fragmentations led to formation of product ions on one side
chain across the DT bond, with the second peptide chain intact
(Figure 1e). Thus, the structure and the sequence of the
dityrosine cross-linked dimerized peptide can be determined by
MS/MS fragmentation in CID, HCD, and ETD. Since, no C−C
bond cleavage occurs at the aromatic ring of the dityrosine in
MS/MS, we can intuitively use the information to localize the
dityrosine bond in a cross-linked peptide with multiple tyrosine
residues by careful evaluation of the fragment ions.
Identification of in Vitro Dityrosine Cross-Linked
Peptides. In vitro dimerization of Aβ by dityrosine cross-
linking is known to occur in the presence of Cu2+/ascorbic acid
or by peroxidases in the presence of H2O2.
34,35 Human
hemoglobin has a pseudoperoxidase activity due to the formation
of ferrylhemoglobin (Fe(IV)O) species (Figure S6) in the
presence of H2O2, which is similar to compound II in
peroxidases. Incubation of Aβ(1−42) with hemoglobin/H2O2
led to the formation of covalently cross-linked Aβ oligomers
(dimers and tetramers) as detected by Western blots of the
fractions from size-exclusion chromatography (SEC) (Figure
2a). The Y10A mutant of Aβ(1−42) did not form such SDS-
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resistant oligomers (Figure 2b). These covalently cross-linked
Aβ peptides were digested by LysC, and the resulting peptides
were fractionated by reverse-phase HPLC at high pH (pH 10)
using fluorescence detection of dityrosine (λex = 325 nm; λem =
410 nm). The dityrosine fluorescent peaks were then analyzed by
ESI-MS/MS using HCD fragmentation (Figure 2d). The major
fluorescent peak at 9.4 min in the high pHHPLC chromatogram
was consistent with the formation of a dityrosine cross-linked
dimer (Figure S7). ESI-MS in LTQ Orbitrap confirmed it to be
the dityrosine cross-linked Aβ(1−16) dimer (Figure 2e and
Figure 2.Catalytic peroxidation of Aβ(1−42) by hemoglobin in the presence of H2O2 induces dityrosine cross-linked oligomers of Aβ. (a)Western blot
analysis after of the fractions with W0−2 antibody from SEC of the mixture of 20 μM Aβ(1−42) with 5 μM hemoglobin and 20 μM H2O2,
demonstrating the formation of oligomeric species of Aβ(1−42) (M, monomers; D, dimers; hemoglobin-Aβ cross-link; and high molecular weight
oligomers). (b)Mutation of Tyr10 clearly illustrates that these oligomeric species of Aβ(1−42) are dityrosine cross-linked, as oligomeric species are not
observed when Y10A mutant of Aβ(1−42) with hemoglobin/H2O2. From left to right, 20 μMY10Amutant of Aβ(1−42) incubated with 20 μMH2O2;
20 μM Y10A mutant of Aβ(1−42) incubated with 5 μM hemoglobin and 20 μM H2O2; 20 μM Y10A mutant of Aβ(1−42) incubated with 5 μM
hemoglobin and 100 μM H2O2; 20 μM Aβ(1−42) incubated with 5 μM hemoglobin and 20 μM H2O2; 10 μM Aβ(1−42) incubated with 5 μM
hemoglobin and 20 μMH2O2. (c) Reaction mechanism of dityrosine cross-link formation from tyrosine. (d) A schematic for bottom-up workflow for
identifying dityrosine cross-links by off-line separation of proteolytically digested dityrosine cross-linked peptides and analysis of the ESI-MS/MS these
peptides using StavroX software. (e) ESI-MS spectra of the dityrosine cross-linked Aβ(1−16) formed due to peroxidation by hemoglobin/H2O2
following LysC digestion and high pH HPLC fractionation. Inset displays the isotopic distribution of +5 charge state (m/z = 782.1556). (f) Annotated
HCD-MS/MS of a dityrosine cross-link peptide between 128FLASVSTVTSKYR140 (hemoglobin α) and 1DAEFRHDSGYEVHHQK16 (Aβ), precursor
ion [M + 5H]5+ at m/z 705.5533 (M = 3522.7665) cross-linked between Y140 of hemoglobin α and Y10 of Aβ, respectively.
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Figure 3. Catalytic peroxidation of α-synuclein by hemoglobin/H2O2 lead to the formation of dityrosine cross-linked oligomers of α-synuclein. (a)
Western blot analysis of oligomerization of α-synuclein by hemoglobin/H2O2. From left to right, 20 μM α-synuclein; 20 μM α-synuclein incubated with
20 μMH2O2; 20 μM α-synuclein incubated with 5 μM hemoglobin; 20 μM α-synuclein incubated with 5 μM hemoglobin and 20 μMH2O2; 20 μM α-
synuclein incubated with 5 μM hemoglobin and 50 μMH2O2 (M, monomers; D, dimers and cross-linked oligomers). (b) Detection of two dityrosine
positive peaks of α-synuclein peptides, peak 1 and peak 2, marked in red from the lane 5 generated in vitro by ferrylhemoglobin. (c) The HCD ESI-MS/
MS spectrum of the dityrosine cross-linked 35EGVLYVGSK43 homodimer with [M + 3H]3+ atm/z 634.0069 (M = 1899.0210) corresponding to peak 2
in (b). (d) The annotated HCD-MS/MS spectrum of the heterodimer of α-synuclein present in the peak 1 dityrosine cross-link between
35EGVTYVGSK43 and 98DQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEGYQYEPEA140 with [M + 4H]4+ at m/z 1444.8856 (M = 5775.5424),
cross-linked between Y39 and Y133. (e) Identification of novel dityrosine cross-links between hemoglobin α/hemoglobin β and α-synuclein and
between hemoglobin α and hemoglobin β by StavroX.
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Figure S8). Upon analyzing other dityrosine positive fractions
(14 min-15 min), we also found a dityrosine cross-link between
127FLASVSTVTSKYR141 (hemoglobin α) and 1DAEFRHDSG-
YEVHHQK16 (Aβ) (Figure 2f), consistent with the 20 kDa
apparent tetramer observed by Western blot (Figure 2, panels a
and b).
Analysis of the other fractions (Figure S7a) demonstrated
multiple dityrosine cross-linked peptides of hemoglobin.
Hemoglobin in red blood cells has been reported to form
dityrosine cross-link adducts when exposed to a constant flux of
H2O2.
36 Hemoglobin is a tetrameric protein consisting of two
pairs of hemoglobin α and hemoglobin β chain. Pure human
hemoglobin (methemoglobin) incubated with H2O2 formed
ferrylhemoglobin (Figure S6), which was then analyzed in ESI-
MS/MS using HCD after in-solution proteolytic digestion.
Dityrosine cross-links occurred between Tyr24, Tyr42, and
Tyr140 in hemoglobin α (Figure S9) and Tyr130 and Tyr145 in
hemoglobin β (Figure S9). Analysis of digested peptides of
human hemoglobin treated with H2O2 revealed the formation of
multiple dityrosine cross-linked peptides involving both
hemoglobin α and hemoglobin β chains (Figure S10a-l and
Table S1). However, this simple bottom-up approach could not
distinguish between intramolecular and intermolecular dityr-
osine cross-links of the hemoglobin tetramer.
Similarly, α-synuclein is also known to form dityrosine cross-
linked oligomers in vitro in the presence of Cu2+/H2O2 or
ascorbic acid as well as by enzymatic peroxidation.37,38 However,
these cross-links have not been fully characterized but are
proposed to represent a neurotoxic oligomer. Western blot
analysis (antibody 4D6) revealed that monomeric α-synuclein
when incubated with hemoglobin/H2O2 forms oligomers
(Figure 3a). Reversed phase HPLC with fluorescence detection
of proteolytically digested α-synuclein oligomers revealed the
presence of two main dityrosine peaks (Figure 3b). ESI-MS/MS
with HCD of peak 2 in Figure 3b revealed the structure as
homodimeric dityrosine cross-link of 35EGVLYVGSK43 peptide
(Figure 3c), confirming dimerization of α-synuclein by
dityrosine cross-linking. This was further verified using
complementary ETD fragmentation (Figure S11). Analysis of
peak 1 in Figure 3b revealed the structure of a heterodimeric DT
cross-link of α-synuclein between 35EGVLYVGSK43 and 98DQL-
GKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDY-
Figure 4. Identification of inter- and intramolecular cross-links using 15N labeled and nonlabeled α-synuclein. (a) Schematic representation of the
workflow for relative quantitation of dityrosine cross-linked peptides. A mixture of nonlabeled protein and 15N labeled protein was incubated with
hemoglobin/H2O2 system for dityrosine cross-link formation. Proteolytic digestion by endoproteinase LysC and a diagram of the possible nonlabeled
and 15N labeled dityrosine cross-linked peptides (i.e., ALAL, ALAH, and AHAH for homodimeric dityrosine cross-link; ALBL, ALBH, AHBL, and AHBH for
heterodimeric dityrosine cross-link). The proteolytic peptides were fractionated by reversed-phase HPLC under high pH conditions.29 The dityrosine
positive fractions from HPLC are subjected to ESI-MS/MS for identification. Relative quantitation can be performed by comparing the
chromatographic peak areas for each form of the cross-linked peptide (EIC) separately as they coelute. (b) MS spectra of normal and 15N-labeled
dityrosine cross-linked heterodimer between 35EGVLYVGSK43 and 98DQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQYEPEA140 (ALBL,
ALBH, AHBL, and AHBH) used for the relative quantitation of these dityrosine cross-linked peptides. (c) Proposed heterodimeric structure of α-synuclein
(PDB: 1XQ8) as determined by the cross-links observed.
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EPEA140 (one missed cleavage) peptides with possible dityrosine
cross-linking between Tyr39 and Tyr125/Tyr133/Ty136
(Figure 3d). The presence of y13α
2+ and y15α
2+ product ions
and a series of y2α−y5α ions lead to the successful identification
and assignment of the position of the cross-linking site in this
heterodimeric dityrosine cross-link of α-synuclein between
Tyr39 and Tyr133. On further evaluation of the peak 1 using
StavroX, software designed to analyze cross-linked peptides,24 it
was possible to find dityrosine cross-linked peptides between α-
synuclein and hemoglobin α/ hemoglobin β (Figure S12). This
also explains the nature of the higher molecular weight bands at
48 and >64 kDa in the Western blot (Figure 3a). All identified
intra- and interprotein dityrosine cross-links between α-
synuclein and hemoglobin α/hemoglobin β were summarized
in the form of a linkage map (Figure 3e and Table S2).
In order to determine if the dityrosine cross-links observed
were intramolecular or intermolecular, the experiment was
performed with a mixture of 15N labeled recombinant α-
synuclein and nonlabeled α-synuclein (Figure 4a and Figure
S13). Intramolecular cross-linking of labeled and nonlabeled A
and B peptides should generate only ALBL and AHBH dityrosine
cross-linked heterodimers (Figure 4a), whereas formation of
mixtures of heavy and light cross-linked peptides (ALBH and
AHBL) would be an outcome of intermolecular cross-linking.
Extracted ion chromatograms (EIC) (Figure 4b) as well as the
MS/MS fragmentation spectra validated that the isotope
scrambling was successful in both the homodimer (Figure S14,
panels a−c) and heterodimer (Figure S14, panels d−g) of α-
synuclein. Homodimer of α-synuclein must be intermolecular
which is also confirmed by the quantitative ratio of the EIC
(Figures S15 and S16). The experimental observation of ALBH
and AHBL heterodimers (Figure 4b) indicate intermolecular
dityrosine cross-linking (Figure S14, panels d−g). The relative
quantitative ratios for the isotopically scrambled heterodimer
were ALBL/ALBH ∼ 0.96, ALBL/AHBL ∼ 2.19, ALBH/AHBL ∼
2.27, ALBL/AHBH∼ 2.02, and AHBL/AHBH∼ 0.92 (Figure 4b and
Figure S16), indicating an intermolecular mechanism for the
heterodimer generation with negligible intramolecular dityrosine
cross-linking in α-synuclein. The quantitative 15N-labeled amino
acid scrambling in dityrosine peptides enabled us to model the
orientation of α-synuclein in solution after considering the
distance constraints imposed by the formation of dityrosine
(Figure 4c).
■ DISCUSSIONS
Dityrosine is an important naturally occurring post translational
modifications (PTM). In structural proteins dityrosine cross-
linking confers stability and elasticity, while in others provides
resistance to proteolysis.2 Dityrosine cross-linked peptides and
proteins have been proposed to have neurotoxic roles in
Alzheimer’s and Parkinson’s Diseases.12,39 The study of
dityrosine in proteins and peptides has been limited to measuring
either derivatized or underivatized dityrosine after acid
hydrolysis.2 However, the extreme conditions required for acid
hydrolysis and requirement of large sample sizes has limited our
understanding of dityrosine in vivo.2,19 The major limitation in
dityrosine research is the inability to determine the location and
identity of the dityrosine cross-link proteins. Here, we addressed
these limitations and difficulties to identify dityrosine cross-
linked peptides using mass spectroscopy in a bottom-up
proteomic workflow. We then used this workflow to understand
the dityrosine cross-links that can occur under oxidative
conditions for two important neurological proteins, Aβ and α-
synuclein. Dityrosine cross-linked oligomers of these proteins are
proposed to be an important factor in the pathophysiology of
Alzheimer’s and Parkinson’s disease, but little molecular detail is
available.
We characterized the fragmentation pattern of model
dityrosine Aβ peptides using CID, HCD, ETD, and ECD with
the hypothesis that a unique fragmentation pattern characteristic
of dityrosine-containing peptides could ensue similar to that
produced by synthetic cross-linkers or disulfide linked peptides
when fragmented by CID or ETD.40−42 However, we did not
find any distinguishing features that would indicate the presence
of a dityrosine cross-link over a linear peptide. This means to
conduct de novo searches for tyrosine (Tyr) peptides in
biological samples, the search space will increase as a square of
the number of Tyr-containing peptides.23 Even though Tyr is in
relatively low frequency peptide (2.92%) (http://web.expasy.
org/docs/relnotes/relstat.html),43 the potential dityrosine pep-
tide database would be every Tyr-containing peptide squared,
which for the human genome results in a searchable space on the
order of 108 sequences. This would lead to an unacceptably high
false discovery rate (FDR) for any computational search
algorithm.44 Thus, alternative approaches will be required to
mine general shotgun proteomic data for dityrosine-containing
peptides from biological samples such as fluorescence.
Dityrosine cross-linked forms of α-synuclein and Aβ are both
implicated as the minimal oligomeric unit required for
neurotoxicity. For Aβ, the only potential dityrosine cross-link
is via Tyr10; however, for α-synuclein, it is not clear which of the
four tyrosine residues are involved in the cross-link. We
demonstrate that α-synuclein can be modified by both
intermolecular and intramolecular dityrosine cross-links. We
used HCD and ETD to characterize the intermolecular
dityrosine cross-linked homopeptide dimer (35EGVLYVGSK43)
(Figure 3c and Figure S11) and cross-link between Tyr39 and
Tyr133 in the heteropeptide dimer (Figure 3d) of α-synuclein.
Using 15N labeled α-synuclein, we demonstrated that a dityrosine
cross-linked heterodimer (AB) preferentially forms by inter-
molecular mechanism (Figure 4b and Figure S16). The distance
constraints imposed by the cross-link between Tyr39 and Tyr133
indicate the formation of a head-to-tail dimer of the two protein
units (Figure 4c). The formation of dityrosine cross-linked
oligomers of α-synuclein could serve as a nucleus to drive
oligomer formation of monomeric α-synuclein,45,46 contributing
to the prion-like activity observed.47
Aβ dimers isolated from the cerebral cortex of post-mortem
AD brain have been reported to induce neuro/synaptotoxicity
and memory disruption.48 The dimers are chemically stable,
consistent with a covalent bond like a dityrosine cross-link or a
longer fragment of the amyloid precursor protein that contains
the Aβ region.49,50 Immunohistochemical detection of dityrosine
have been reported in the affected regions in AD brain, enriched
in the amyloid plaques.12 Dityrosine cross-linked Aβ(1−42) is
more toxic in vitro than monomeric Aβ(1−42).30 However,
dimeric Aβ species extracted from the AD brain is poorly
characterized, and hence, the technique developed here provides
a platform for future studies in determining both the presence as
well as the extent of dityrosine cross-linked Aβ in AD.
Evaluation of additional HPLC fractions positive for dityrosine
fluorescence demonstrated cross-links between Aβ with
hemoglobin (Figure 2f) and α-synuclein with hemoglobin as
depicted in the linkage map (Figure 3e). Since α-synuclein and
hemoglobin are abundant in red blood cells51 and neurons,52,53
we can now examine such species in human samples, as potential
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biomarkers for Parkinson’s Disease. The formation of cross-
linked oligomers has some key differences to noncovalently
linked oligomers, including a long lifetime due to protease
resistance of the dityrosine moiety.
We have also applied the knowledge of the fragmentation
feature of dityrosine cross-linked peptides to identify the possible
tyrosine radical sites in ferrylhemoglobin, which form dityrosine
cross-links in vitro. Dityrosine formation is an extremely fast
process (k = 3.8−5× 108M−1 s−1, Figure 2c),54 and identification
of dityrosine cross-linked peptides will provide the hitherto
unknown knowledge of how proteins interact with their
environment under oxidative and/or nitrative stress. The
formation of ferrylhemoglobin from methemoglobin has been
investigated by absorption, EPR spectroscopy, and resonance
Raman spectroscopy.36,55 The ferrylhemoglobin (Figure S6),
Fe(IV)O, species with a radical centered on the heme-
porphyrin rapidly decays into Fe(IV)O species with radical
distributed on aromatic amino acid of the globin chain. Analysis
of the dityrosine pairs of hemoglobin indicate that radical
formation not only can occur at Tyr 42 of hemoglobin α chain as
previously reported,56 but radicals form at Tyr24 and Tyr140 in
hemoglobin α as well as on Tyr130 and Tyr145 of hemoglobin β
(Figure S9). Mildly oxidatively modified hemoglobin has an
increased susceptibility to proteasomes, by partial unfolding and
exposing the hydrophobic amino acid to the surface, while the
highly oxidized hemoglobin is prone to aggregation, making it
resistant to proteolysis.57 Thus, understanding how these
dityrosine cross-links of hemoglobin-α/hemoglobin-β alter the
tetrameric structure and lead to aggregation is important for
elucidating its physiological processing and may provide insight
into the mechanism of blood coagulation.58
■ CONCLUSION
Oxidative stress and nitrative stress lead to alteration in every
level of protein structure as well as it normal function. One of
these changes is the formation of the oxidative covalent cross-
linkage between two tyrosine residues known as the dityrosine
bond. Immunohistochemical detection of dityrosine has been
confirmed in Aβ plaques in AD brain as well as in Lewy bodies in
the brains with PD. Despite advancements in quantitatively
determining free dityrosine, information regarding specific
protein targets and dityrosine cross-linking sites in the proteins
is very limited. Here we report the development of generic rules
of fragmentation for dityrosine cross-linked peptides in tandem
mass spectrometry, which allowed for automated identification
of dityrosine cross-links in peptides of Aβ, hemoglobin, and α-
synuclein generated in vitro by enzymatic peroxidation.
Oxidative stress is universal, and this methodology opens up
the potential in identifying dityrosine cross-linked proteins that
can serve as biomarkers in diverse pathological conditions such as
AD, PD, atherosclerotic plaques, cancer, and aging. We also
report that isotope scrambling during dityrosine cross-linking
can be intuitively used for assessment in the structural changes in
proteins undergoing oxidative stress. However, alternative
methods have to be developed for using this tool for identifying
and characterizing this natural PTM in peptides and proteins
present in biological samples such as the human proteome.
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